DIRC2 anticorps (AA 51-150) (Biotin)

N° du produit ABIN1398169

Cet anticorps Lapin Polyclonal détecte spécifiquement DIRC2 dans WB, ELISA, IHC (fro) et IHC (p). Il présente une réactivité envers Humain et Rat.

Aperçu rapide pour DIRC2 anticorps (AA 51-150) (Biotin) (ABIN1398169)

Antigène: DIRC2 (Disrupted in Renal Carcinoma 2 (DIRC2))

Reactivité: Humain, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp DIRC2 est conjugé à/à la Biotin

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-DIRC2 anticorps (Biotin)

Épitope: AA 51-150

Réactivité croisée: Humain, Rat

Homologie: Mouse,Dog,Sheep,Pig,Horse,Rabbit

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human DIRC2

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur DIRC2

Antigène: DIRC2 (Disrupted in Renal Carcinoma 2 (DIRC2))

Autre désignation: DIRC2

Sujet:

Synonyms: Disrupted in renal carcinoma protein 2, DIRC 2, Disrupted in renal cancer protein 2, Disrupted in renal carcinoma 2, FLJ14784, NP_116228, RCC 4, RCC4, Renal cell carcinoma 4, DIRC2_HUMAN.

Background: Belonging to the major facilitator superfamily, DIRC2 (disrupted in renal carcinoma protein 2) is a 478 amino acid multi-pass membrane protein that is primarily expressed in kidney proximal tubular cells. The genes encoding DIRC2 and DIRC3 are located at a translocation breakpoint which occurs frequently in individuals affected by familial renal cell carcinoma. Fusion transcripts that result from these translocations may affect normal protein function. This evidence suggests that, due to its chromosomal location, deregulation of the DIRC2 gene may cause haploinsufficiency and therefore result in the onset of tumor growth. There are two isoforms of DIRC2 which are produced as a result of alternative splicing events.

ID gène: 84925